Webinar | 28 September 2022 | 8:30 a.m. - 10:00 a.m. BST | 9:30 a.m. - 11:00 a.m. CET | 3:30 p.m. - 5:00 p.m. CST | 4:30 p.m. - 6:00 p.m. JST

APAC Life Sciences and Health Care Webinar Series - Spotlight on Greater China - Session 3

Webinar No. 3: Out-licensing to Chinese counterparties, including related necessary IP protections

We are delighted to invite you to the third session of our APAC life sciences and health care webinar series on Wednesday, 28 September 2022.

China’s pharmaceutical sector is experiencing a monumental shift from a generics-focused system into one that values novel drug discovery and development. This shift bodes well for non-PRC biotech companies that have early-stage compounds under development, but lack the capital, bandwidth or regulatory experience to develop them for the Chinese market.

There are a host of issues a licensor should address before entering into a license agreement with the Chinese counterparty, not least to protect its IP. Those issues range from picking the right licensee entity, registering the license as a technology import and export contract if required , considering restrictions on the assignment of IP improvements all the way through to choosing the right governing law and dispute resolution mechanism to facilitate enforcement. These issues are complex, not always intuitive and are always a lot harder to fix after the fact (and in some cases they may not be fixable at all).

In this session, we will discuss the common perils and pitfalls a non-PRC licensor may face when out-licensing to Chinese counterparties.

If you have any questions, please submit them in advance and our speakers will seek to address them during the webinar.

We hope you can join us.

Future session:

• Session no. 4 – IP (the newly-introduced systems in China for patent term extension and patent linkage; and Chinese anti-monopoly issues when settling patent infringement actions)